Related Experiment Video
Updated: Feb 3, 2026
08:43
Chronic Ovine Model of Right Ventricular Failure and Functional Tricuspid Regurgitation
Published on: March 17, 2023
1.1K
Association Between 3-Iodothyronamine (T1am) Concentrations and Left Ventricular Function in Chronic Heart Failure
Jeppe Lerche la Cour1, Heidi M Christensen1,2, Josef Köhrle3
1Department of Endocrinology, Herlev University Hospital, Herlev, Denmark.
The Journal of Clinical Endocrinology and Metabolism
|November 2, 2018
Summary
Thyroid hormone metabolite 3-iodothyronamine (T1am) is elevated in chronic heart failure (CHF) patients. Higher T1am levels are linked to reduced left ventricular ejection fraction (LVEF), suggesting a direct cardiac impact.
Area of Science:
- Cardiology
- Endocrinology
- Metabolomics
Background:
- Thyroid hormone metabolites, such as 3-iodothyronamine (T1am), may influence cardiac function.
- Previous rodent studies indicate T1am can decrease left ventricular ejection fraction (LVEF).
Purpose of the Study:
- To determine T1am concentrations in patients with chronic heart failure (CHF), including those with cardiac cachexia.
- To investigate the association between T1am levels, LVEF, and cardiac biomarkers in CHF patients without thyroid disease.
Main Methods:
- A cross-sectional study involving three groups: CHF with cachexia (CAC), CHF without cachexia (non-CAC), and control (C) patients.
- T1am and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured using immunoassay techniques.
- LVEF was assessed, and thyroid hormone levels (TSH, T4, T3) were analyzed.
Main Results:
- Serum T1am concentrations were significantly higher in CHF patients (non-CAC and CAC) compared to controls.
- A significant negative association was found between T1am levels and LVEF, even after adjusting for confounding factors.
- T1am levels showed a trend towards association with NT-proBNP, a marker of heart failure severity.
Conclusions:
- Elevated serum T1am levels are present in patients with CHF, with the highest concentrations observed in those with cardiac cachexia.
- Increasing T1am is independently associated with reduced LVEF, suggesting a potential direct detrimental effect on the human heart.
More Related Videos
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.7K
09:40Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
Published on: May 13, 2019
11.1K
Related Concept Videos
01:29Heart Failure II: Pathophysiology
929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
01:17Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
01:27Heart Failure I: Introduction
886
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
01:22Heart Failure VI: Adjunct Therapies
340
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
01:22Heart Failure Drugs: Diuretics
971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
01:30Heart Failure V: Medical Management
319
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319